A patent that hasn’t even issued yet sent a thinly traded diabetes stock up 100% in a single session on 25 times its normal volume. A Utah AV equipment maker filed routine merger paperwork and jumped 98% after hours, even though the deal leaves its own shareholders with barely a tenth of the combined company. Junior gold stocks had their best week in years after a weak jobs report reset the market’s Fed expectations, and a Mexican gold driller caught that wave with its best intercept yet.
Biotech & Life Sciences
Creative Medical Technology Jumps 100% After a New Type 1 Diabetes Patent Allowance
Creative Medical Technology Holdings (Nasdaq: CELZ) received a Notice of Allowance from the USPTO on August 6 for a new patent covering an exosome-based immunotherapy for Type 1 diabetes, part of its MyeloCelz platform designed to suppress the autoimmune attack that destroys insulin-producing pancreatic beta cells. The stock jumped more than 100% the same day on roughly 25 times its normal trading volume.
A patent allowance is a real regulatory step, but it protects intellectual property rather than proving a therapy works in humans, and it is not the same as an issued patent or clinical data. Independent market commentary flagged that the size of the move looks disproportionate to the news itself; Creative Medical is a thinly traded, low-float stock, and momentum around older pipeline updates likely amplified the reaction well beyond what the patent news alone would justify. The company reports roughly 60 issued patents and pending applications across its regenerative medicine portfolio, with two further diabetes programs, CELZ-101 and CELZ-201, already in clinical testing.
Tech & Innovation
ClearOne Jumps Nearly 100% on Merger Paperwork That Leaves Its Own Shareholders With a Sliver of the Company
ClearOne (Nasdaq: CLRO) shares jumped as much as 98% after hours on August 5 following an SEC filing that canceled outstanding warrants and locked in an employment agreement for an incoming CFO, both procedural steps tied to its already-announced merger with Cortigent, a neurotechnology subsidiary of Vivani Medical. Cortigent develops brain-computer interface and visual prosthesis technology, including work aimed at restoring arm and hand motion after stroke.
The filing itself contained no new business results. What it confirmed is the ownership math behind the deal: Vivani is set to own 59.4% to 67.5% of the combined company once the merger closes, while ClearOne’s existing shareholders retain just 12.7% to 14.4%. ClearOne will be renamed Cortigent Holdings and trade under a new ticker, CRGT, once the transaction is complete; ClearOne’s own business, in the meantime, is being absorbed into a much larger structure it does not control.
Mining & Minerals
Tocvan Ventures Hits Its Best Gold Intercept Yet as Junior Gold Stocks Post Their Strongest Week in Years
Tocvan Ventures (CSE: TOC, OTCQB: TCVNF) drilled 215 meters grading 0.6 g/t gold from 36.6 meters downhole at its Gran Pilar project in Sonora, Mexico, announced August 6, one of the best intercepts the company has recorded on the property to date. The result landed in the middle of a broad rally across junior gold names: the VanEck Junior Gold Miners ETF gained more than 22% over the same week after a weak US jobs report pushed gold and silver prices higher on renewed expectations of Fed rate cuts.
Some of Tocvan’s move this week is the stock riding a sector-wide wave rather than this result alone; the TSX Venture Composite, which leans heavily on junior miners, gained 8% over the same period. On the numbers themselves, 0.6 g/t is a modest grade by underground standards. The real story is the thickness and continuity of a near-surface zone the company is advancing toward a planned pilot mine, not a bonanza-grade hit.
Green Energy & Cleantech
Standard Uranium Lands a $3 Million Strategic Investment From a Southeast Asian Energy Conglomerate
Standard Uranium (TSXV: STND, OTCQB: STTDF) agreed to a $3 million non-brokered private placement with an arm’s-length energy conglomerate from a Southeast Asian nation, announced August 7, which will give the investor roughly 19.7% ownership of the company on a non-diluted basis. Standard Uranium did not name the investor in its release.
That is an unusual level of opacity for a deal handing over nearly a fifth of the company. Standard Uranium is a project generator working across the Athabasca Basin, one of the world’s highest-grade uranium districts, and the capital is earmarked for its 2026 exploration program at Davidson River and other targets. The placement is dilutive to existing shareholders and, like any private placement, remains subject to TSX Venture Exchange approval before it closes.
What to Watch Next
The patent still has to formally issue, and the exosome program itself remains preclinical. Its two clinical-stage diabetes programs, CELZ-101 and CELZ-201, are the ones to watch for actual trial data.
No firm closing date has been announced. Once it closes, ClearOne will be renamed Cortigent Holdings and begin trading under the ticker CRGT, majority owned by Vivani Medical.
Tocvan has additional holes pending along the Mezquite trend where this intercept was drilled. The company has also flagged a planned pilot mine at Gran Pilar as its longer-term target.
The placement remains subject to acceptance by the TSX Venture Exchange. No closing date has been disclosed yet.
Sources
- Creative Medical Technology Holdings Receives Notice of Allowance for New U.S. Patent, GlobeNewswire, August 6, 2026
- Creative Medical Technology Holdings shares surge as traders appear to latch onto earlier pipeline updates and a tiny-float setup, QuiverQuant, August 6, 2026
- ClearOne Shares Jump After Hours On Merger, Shareholder Approval, Benzinga, August 5, 2026
- ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., SEC Form 8-K Exhibit 99.1
- Tocvan Drills Significant Discovery On Mezquite Trend Gran Pilar, 215M Of 0.6 G/T AU, Junior Mining Network, August 6, 2026
- Gold miners surge more than 20% in breakout week, MINING.COM, August 7, 2026
- Standard Uranium Reaches Agreement for $3 Million Strategic Investment, Junior Mining Network, August 7, 2026
Editorial Disclosure
Tickers discussed in this article: CELZ (Creative Medical Technology Holdings), CLRO (ClearOne), TOC / TCVNF (Tocvan Ventures), and STND / STTDF (Standard Uranium). aktiego.com has received no compensation from any company, IR firm, or third party in connection with this coverage, and no aktiego.com staff member holds a position in any security named above. Press release dates and primary sources were verified against company IR pages, GlobeNewswire, SEC EDGAR, and Newsfile Corp, and all items fall within the August 2 to 8, 2026 coverage window. All companies named are under $500 million USD in market capitalization as of the dates referenced above, so no size flag applies under this publication’s disclosure tiers. Momentum and low-float disclosure: Creative Medical Technology Holdings’ single-day move followed a real regulatory event, but independent commentary suggests the size of the reaction may reflect thin float and momentum trading more than the news itself; a patent allowance is not an issued patent and does not constitute clinical validation. Dilution disclosure: ClearOne shareholders are set to retain only 12.7% to 14.4% of the combined company once its merger with Cortigent closes, with Vivani Medical taking majority control; Standard Uranium’s private placement is dilutive to existing shareholders and remains subject to TSX Venture Exchange approval. Sector-wide versus company-specific catalyst disclosure: Tocvan Ventures’ share price this week reflects both its own drill result and a broad rally across junior gold and silver equities following a weak US jobs report; readers should not attribute the full move to company-specific news alone. Jurisdiction disclosure: Tocvan Ventures’ Gran Pilar project is located in Sonora, Mexico, a jurisdiction carrying its own permitting and operating considerations distinct from Canadian or US projects. These are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only, aktiego.com is not a registered investment advisor, and nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
